文献速递胰腺与胆道疾病消化道肿瘤与早癌

白细胞介素22信号调控腺泡细胞可塑性促进小鼠胰腺肿瘤发生

Interleukin 22 Signaling Regulates Acinar Cell Plasticity to Promote Pancreatic Tumor Development in Mice.
PubMed 文献 · Gastroenterology · 2019-12-14

该研究利用PKCY小鼠及IL22敲除模型,发现IL22在胰腺炎和肿瘤发生中升高,且为肿瘤发生所必需;IL22通过JAK-STAT3和MEK通路促进腺泡-导管化生、干细胞特征及上皮-间质转化,抑制STAT3可阻断这些效应,且IL22高表达与患者生存期缩短相关。

要点

  • IL22在胰腺炎和胰腺肿瘤发生中表达升高,主要由Th22细胞产生。
  • IL22敲除可阻止PKCY小鼠发生癌前病变和胰腺肿瘤。
  • IL22通过STAT3和MEK通路促进腺泡-导管化生及肿瘤细胞干性。

核心结论

  • IL22在胰腺炎和胰腺肿瘤发生中升高,且为小鼠肿瘤发生和进展所必需。
  • IL22促进腺泡-导管化生、干细胞特征及上皮-间质转化标志物表达,STAT3抑制剂可阻断这些效应。
  • PDAC中IL22表达升高与患者生存期缩短相关。

研究设计与样本

  • 使用Pdx1-Cre;LSL-KrasG12D;Trp53+/-;Rosa26EYFP/+(PKCY)小鼠及IL22敲除的PKCY小鼠。
  • 部分小鼠给予雨蛙素诱导胰腺炎。
  • 将PD2560胰腺癌细胞系原位注射到C57BL/6或Il22-/-小鼠,监测肿瘤发展。
  • 尾静脉注射胰腺细胞并量化肺转移。
  • 培养C57BL/6小鼠和切除人胰腺的腺泡,用IL22及药理学抑制剂处理,并用shRNA敲低蛋白。

主要发现

  • 小鼠胰腺中IL22和IL22受体表达高于其他组织,且随胰腺炎和肿瘤发生而增加。
  • 流式细胞术显示IL22主要由Th22细胞产生。
  • PKCY Il22-/-小鼠未发生癌前病变或胰腺肿瘤。
  • IL22增加培养腺泡细胞的导管化生标志物表达,JAK抑制剂鲁索替尼、MEK抑制剂曲美替尼及STAT3敲低可阻止该效应。
  • 注射到Il22-/-小鼠的胰腺细胞形成的肿瘤小于注射到C57BL/6小鼠的肿瘤。

临床怎么用

  • IL22-STAT3信号轴可能成为胰腺癌化学预防或治疗的潜在靶点。
  • STAT3抑制剂(如鲁索替尼)在临床前模型中可阻断IL22的促肿瘤效应。
  • IL22/STAT3高表达可能提示胰腺癌患者预后不良。

局限性

  • 研究主要基于小鼠模型和体外实验,人体数据仅为26例PDAC和5例非肿瘤胰腺标本的免疫组化分析。
  • IL22在人类胰腺癌发生发展中的确切作用仍需进一步临床研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy that invades surrounding structures and metastasizes rapidly. Although inflammation is associated with tumor formation and progression, little is known about the mechanisms of this connection. We investigate the effects of interleukin (IL) 22 in the development of pancreatic tumors in mice. METHODS: We performed studies with Pdx1-Cre;LSL-KrasG12D;Trp53+/-;Rosa26EYFP/+ (PKCY) mice, which develop pancreatic tumors, and PKCY mice with disruption of IL22 (PKCY Il22-/-mice). Pancreata were collected at different stages of tumor development and analyzed by immunohistochemistry, immunoblotting, real-time polymerase chain reaction, and flow cytometry. Some mice were given cerulean to induce pancreatitis. Pancreatic cancer cell lines (PD2560) were orthotopically injected into C57BL/6 mice or Il22-/-mice, and tumor development was monitored. Pancreatic cells were injected into the tail veins of mice, and lung metastases were quantified. Acini were collected from C57BL/6 mice and resected human pancreata and were cultured. Cell lines and acini cultures were incubated with IL22 and pharmacologic inhibitors, and protein levels were knocked down with small hairpin RNAs. We performed immunohistochemical analyses of 26 PDACs and 5 nonneoplastic pancreas specimens. RESULTS: We observed increased expression of IL22 and the IL22 receptor (IL22R) in the pancreas compared with other tissues in mice; IL22 increased with pancreatitis and tumorigenesis. Flow cytometry indicated that the IL22 was produced primarily by T-helper 22 cells. PKCY Il22-/-mice did not develop precancerous lesions or pancreatic tumors. The addition of IL22 to cultured acinar cells increased their expression of markers of ductal metaplasia; these effects of IL22 were prevented with inhibitors of Janus kinase signaling to signal transducer and activator of transcription (STAT) (ruxolitinib) or mitogen-activated protein kinase kinase (MEK) (trametinib) and with STAT3 knockdown. Pancreatic cells injected into Il22-/- mice formed smaller tumors than those injected into C57BL/6. Incubation of IL22R-expressing PDAC cells with IL22 promoted spheroid formation and invasive activity, resulting in increased expression of stem-associated transcription factors (GATA4, SOX2, SOX17, and NANOG), and increased markers of the epithelial-mesenchymal transition (CDH1, SNAI2, TWIST1, and beta catenin); ruxolitinib blocked these effects. Human PDAC tissues had higher levels of IL22, phosphorylated STAT3, and markers of the epithelial-mesenchymal transition than nonneoplastic tissues. An increased level of STAT3 in IL22R-positive cells was associated with shorter survival times of patients. CONCLUSIONS: We found levels of IL22 to be increased during pancreatitis and pancreatic tumor development and to be required for tumor development and progression in mice. IL22 promotes acinar to ductal metaplasia, stem cell features, and increased expression of markers of the epithelial-mesenchymal transition; inhibitors of STAT3 block these effects. Increased expression of IL22 by PDACs is associated with reduced survival times.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Perusina Lanfranca M, Zhang Y, Girgis A, et al. Interleukin 22 Signaling Regulates Acinar Cell Plasticity to Promote Pancreatic Tumor Development in Mice. Gastroenterology. 2019. PMID: 31843590. doi:10.1053/j.gastro.2019.12.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。